Atara Biotherap | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 3.453 M

Revenue: As of FY2025 Q3, the actual value is USD 3.453 M, beating the estimate of USD 2.739 M.

EPS: As of FY2025 Q3, the actual value is USD -0.32, beating the estimate of USD -0.692.

EBIT: As of FY2025 Q3, the actual value is USD -2.869 M.

Financial Update: Third Quarter 2025 Financial Results

Cash, Cash Equivalents, and Short-term Investments

• As of September 30, 2025: $13.7 million
• As of June 30, 2025: $22.3 million

Net Cash Used in Operating Activities

• Third Quarter 2025: $9.8 million
• Third Quarter 2024: $4.0 million
• Increase of $5.8 million YoY, primarily due to a decrease in cash receipts from Pierre Fabre

Net Loss

• Third Quarter 2025: $4.3 million, or $0.32 per share
• Third Quarter 2024: $21.9 million, or $2.93 per share

Total Revenues

• Third Quarter 2025: $3.5 million
• Third Quarter 2024: $40.2 million
• Decrease of $36.7 million YoY, primarily due to accelerated recognition of deferred revenue and milestone payments in 2024

Total Costs and Operating Expenses

• Third Quarter 2025: $7.0 million
• Third Quarter 2024: $61.9 million

Research and Development Expenses

• Third Quarter 2025: $2.9 million
• Third Quarter 2024: $43.9 million

General and Administrative Expenses

• Third Quarter 2025: $4.0 million
• Third Quarter 2024: $10.4 million

2025 Outlook and Cash Runway

• Atara is eligible to receive a $40 million milestone payment upon FDA approval of the tab-cel BLA. Additionally, Atara will receive double-digit tiered royalties on net sales and milestones related to commercial sales of EBVALLO. Full-year 2025 operating expenses are anticipated to decrease by at least 60% compared to 2024, driven by the transition of tab-cel activities and associated costs to Pierre Fabre Laboratories and operational efficiencies implemented in the first half of the year. Cash, cash equivalents, and short-term investments as of September 30, 2025, combined with the milestone payment upon tab-cel BLA approval, will provide significant cash runway and flexibility for Atara to execute on its strategic priorities.